These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 22372848)

  • 1. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
    Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI
    Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy.
    Song MK; Chung JS; Seol YM; Kim SG; Shin HJ; Choi YJ; Cho GJ; Shin DH
    Ann Oncol; 2010 Jan; 21(1):140-4. PubMed ID: 19887468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
    Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
    Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM
    Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
    Batty N; Ghonimi E; Feng L; Fayad L; Younes A; Rodriguez MA; Romaguera JE; McLaughlin P; Samaniego F; Kwak LW; Hagemeister FB
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):15-8. PubMed ID: 23137719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
    Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN
    Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
    Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
    Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
    Keam B; Ha H; Kim TM; Jeon YK; Lee SH; Kim DW; Kim CW; Heo DS
    Leuk Lymphoma; 2015 Jul; 56(7):2032-8. PubMed ID: 25382617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
    Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
    J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.